Companies › Beijing Tide Pharmaceutical
5 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 2, 2 Phase 3; Other, Oncology, Respiratory; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TDI01 suspension | – | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF); GVHD, Chronic | Aug 2027 |
| TRD205 Tablets | – | Phase 2 | Postoperative Analgesia After Unilateral Hip Arthroplasty | – |
| TCC1727 tablet KRAS inhibitor | – | Phase 1 | Patients with Advanced Solid Tumors; Solid Cancers | Sep 2028 |
| benmelstobart | – | Phase 1 | Solid Cancers; Non-Clear Cell Renal Cell Carcinoma; Natural Killer T-cell Lymphoma; Non-Small Cell Lung Cancer | Sep 2028 |
| CPD704 Inhalation Suspension | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05970016 | TCC1727 tablet | Phase 1 | Patients with Advanced Solid Tumors | Oncology | Jul 2025 |
| NCT07301203 | CPD704 Inhalation Suspension | Phase 1 | Healthy | Other | Jun 2026 |
| NCT07543796 | TRD205 Tablets | Phase 2 | Postoperative Analgesia After Unilateral Hip Arthroplasty | Other | Jun 2026 |
| NCT06733051 | benmelstobart | Phase 2 | Natural Killer T-cell Lymphoma | Oncology | Dec 2026 |
| NCT07881900 | benmelstobart | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | Oncology | Jun 2027 |
| NCT06528847 | benmelstobart | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT06169722 | TDI01 suspension | Phase 1 | GVHD, Chronic | Respiratory | Aug 2027 |
| NCT07371663 | TCC1727 tablet | Phase 1 | Solid Cancers | Oncology | Sep 2028 |
| NCT07371663 | benmelstobart | Phase 1 | Solid Cancers | Oncology | Sep 2028 |
| NCT07464912 | TDI01 suspension | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Jul 2029 |
No annotated target.
–
Haihe Biopharma Shanghai Huaota Biopharmaceutical J-Pharma Ranok Therapeutics (Hangzhou) Monte Rosa Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.